420
Participants
Start Date
September 30, 2025
Primary Completion Date
June 30, 2030
Study Completion Date
July 31, 2030
Administration of indocyanine green (ICG) and fluorescence imaging
Patients with clinical and lab findings consistent with a diagnosis of NSTI who consent to this study will receive a one-time, weight-appropriate dose of ICG (0.2 mg/kg, in accordance with FDA-approved recommendations). Each patient will undergo fluorescence imaging immediately before and after administration of ICG.
NOT_YET_RECRUITING
University of Pittsburgh Medical Center, Pittsburgh
NOT_YET_RECRUITING
University of Pennsylvania, Philadelphia
NOT_YET_RECRUITING
Emory University/Grady Memorial Hospital, Atlanta
NOT_YET_RECRUITING
Vanderbilt University, Nashville
NOT_YET_RECRUITING
University of Michigan, Ann Arbor
NOT_YET_RECRUITING
University of California, Los Angeles, Los Angeles
NOT_YET_RECRUITING
Stanford University, Stanford
RECRUITING
Dartmouth-Hitchcock Medical Center, Lebanon
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eric R. Henderson
OTHER